P&G Health Commemorates Iron Deficiency Day with Launch of “The First Iron Deficiency Diagnosis and Counseling Guide” for Pharmacists


  • South East Asia and Africa continue to report the highest anemia prevalence rates, accounting for 85 percent of reported cases worldwide.

  • Launched in conjunction with Iron Deficiency Day 2021, the guide with its new 4-step framework will provide pharmacists with a structured guide to better diagnose and advise iron deficiency anemia (IDA)

SINGAPORE, Dec. 2, 2021 / PRNewswire / – P&G Health, the healthcare division of Procter & Gamble (NYSE: PG), announced the launch of the “First Iron Deficiency Diagnosis and Counseling Guide” for Pharmacists on the occasion of Iron Deficiency Day 2021. It was developed using the American Society of Health-System Pharmacists (ASHP) guidelines on patient education and counseling by pharmacists and physicians. IDA-specific management considerations from the peer-reviewed literature. The guide, with its new 4-step framework, will allow pharmacists to better engage and advise patients about iron deficiency anemia (IDA).

(PRNewsfoto / Procter & Gamble)

Today, about 2.3 billion people worldwide suffer from anemia, one in two of which is attributed to IDA. Patients present with symptoms such as frequent fatigue, dizziness, pallor and impaired immunity, which impacts their quality of life, mobility and productivity. Many patients remain asymptomatic. South East Asia and Africa continue to report the highest anemia prevalence rates, accounting for 85 percent of reported cases worldwide.

In the absence of an existing or consistent guide for dealing with IDA, 84%[1] of patients end up being underdiagnosed especially as the symptoms of AID are vague, some patients being asymptomatic.

“P&G Health is engaged in awareness and education efforts on iron deficiency anemia, a disease affecting large parts of our population across Asia. Iron deficiency anemia inhibits a person’s ability to live to their full potential. As pharmacists are among the first line of contact for patients, they are well placed in the community to have a significant impact on public health. We have found that the lack of a standardized guide creates the possibility of underdiagnosis, incomplete counseling or worse. With this “first iron deficiency diagnostic and counseling guide”, we aim to provide pharmacists with a structured framework for diagnosing and counseling iron deficiency, helping consumers to live healthier and more vibrant lives. . “ share Aalok Agrawal, Senior Vice President, P&G Health – Asia Pacific, India, Middle East and Africa.

Dr Catherine duggan, Chairman and CEO, International Pharmaceutical Federation (FIP) declared, “FIP’s vision is of a world where everyone has access to safe, effective, quality and affordable medicines and health technologies, as well as pharmaceutical care services provided by pharmacists, in collaboration. with other health professionals. FIP is pleased to see these guidelines published to help pharmacists deal with such an important condition, globally and, in particular through Indonesia, India and Philippines. We look forward to seeing how these guidelines are used in practice and thus have contributed to better patient outcomes. ”

Armed with this structured guide, pharmacists would be even better equipped to detect high-risk patients, identify their symptoms and advise them on nutritional and lifestyle changes. It will be gradually rolled out around the world from South East Asia and India.

New framework in 4 steps

The 4-step framework guides pharmacists in approaching patients with AID or those suspected of having AID in a logical and sequential manner based on ASHP guidelines. The framework identifies four stages that pharmacists must go through: establish, assess, educate and verify.

1. Establish
In the first step, pharmacists are guided to establish a relationship with the patient, make a diagnosis and identify a suspected AID. Building on existing principles of communicating with patients, pharmacists are advised to identify themselves and communicate in the patient’s primary spoken language before determining whether the patient has been diagnosed with AID. Thus, pharmacists are advised to inform the patient of the expected duration of the session before obtaining the patient’s consent to participate.

2. Assess
Taking the second step, pharmacists should assess the patient’s knowledge of ADI and the use of diagnostic tools that can identify ADI. It depends on whether the patient is already diagnosed or is suspected of having the disease.

For the former, pharmacists are advised to assess the patient’s current knowledge of his condition, his attitude towards his condition and to check whether any medications have been prescribed previously as well as any dietary changes made. For the latter, pharmacists are advised to assess whether the patient is at high risk. This would be done by recording the clinical signs and symptoms while using laboratory tests to confirm the diagnosis.

3. Educate
When completed, the third step is aimed at educating the patient on the correct dosage, highlighting the results of taking the prescribed medication, understanding the underlying issues, and providing additional general information. This includes recommendations for dietary changes and patient education about oral iron supplementation. Pharmacists are also invited to recall the importance of food diversification.

4. To verify
The final step of the framework would require pharmacists to verify patient knowledge and understanding. Pharmacists are advised to verify the patient’s understanding of IDA, medications prescribed, and suggested lifestyle changes needed to manage the condition. To focus on understanding the use of drugs and their effects, patients must be able to describe the effects. Finally, pharmacists should observe their patients’ ability to use drugs and their attitudes towards ADI.

Using the framework, pharmacists would be able to help patients on their journey to self-care. This would include sensitizing and educating patients about ADI while ensuring familiarity and taking the necessary steps among patients to improve their own health when dealing with ADI.

[1] Kassebaum NJ et al. Hematol Oncol Clin North America 2016; 30: 247-308; 2. Fonseca C et al. Med J Intern 2016; 46: 470-8.

About P&G Health:

P&G Health, the healthcare division of the P&G Company, competes in the largest and most dynamic $ 200 billion Personal and oral health care categories and markets to drive consumer-centric innovation that enables our consumers to live longer, healthier and more vibrant lives. The P&G Health portfolio includes leading brands in Respiratory with Vicks® and Nasivin®, Pregnancy with Femibion® and Clearblue®, Oral Care with Crest® and Oral-B®, Vitamin and mineral supplementation with Bion3®, Seven Seas®, Evion® and Sangobion®, Digestive Wellness with Metamucil®, Prilosec OTC®, Pepto Bismol® and Align®, Nerve Care with Neurobion® and Pain Relief with Dolo-Neurobion®.

About Procter & Gamble:

P&G serves consumers around the world with one of the strongest portfolios of trusted, quality and leadership brands including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze ®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks® and Whisper® . The P&G community includes operations in approximately 70 countries around the world.

SOURCE Procter & Gamble


Comments are closed.